Praxis Precision Medicines - Biotech company reports breakthrough in study results!

Business Driver: Praxis Precision Medicines (PRAX) specializes in the development of therapies for central nervous system (CNS) disorders, utilizing proprietary platforms such as Cerebrum and Solidus. A key area of research is the treatment of severe genetic epilepsies (DEEs), where there are currently very few approved medications or treatment procedures. With Relutrigine, they have a promising drug candidate for the treatment of rare, severe genetically caused epileptic disorders with early seizure manifestation and high medical need, which could...